Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
Philipp Diehl, Christoph Bode, Daniel Duerschmied Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany Abstract: Vorapaxar (ZONTIVITY™, formerly known as SCH 530348) is a specific, orally active antagonist of the protease-activated receptor-1 (PAR...
שמור ב:
| Principais autores: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2015-08-01
|
| סדרה: | Therapeutics and Clinical Risk Management |
| גישה מקוונת: | http://www.dovepress.com/clinical-potential-of-vorapaxar-in-cardiovascular-risk-reduction-in-pa-peer-reviewed-article-TCRM |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|